- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
The side effects of bimetinib require focused monitoring of cardiac, hepatic, and ocular toxicity, while also paying attention to standardized ...
Binimetinib is a MEK inhibitor primarily used for the treatment of metastatic melanoma and non-small cell lung cancer, and should be used in co...
Bimetinib should focus on the risks of cardiomyopathy, hepatotoxicity, and retinopathy, and regular monitoring of relevant indicators and timel...
Binimetinib is an oral inhibitor targeting MEK1/2 kinase, mainly used to treat melanoma and non-small cell lung cancer carrying BRAFV600E/K mut...
Pacritinib is a novel kinase inhibitor used to treat bone marrow fibrosis with severe thrombocytopenia. Its clinical application should focus o...
Pacritinib is a JAK2/FLT3 inhibitor used to treat bone marrow fibrosis, with a standard dose of 200mg per dose, taken orally twice daily. In te...
Common side effects of Pacritinib include diarrhea, nausea, and fatigue, which require targeted management measures. The following provides a d...
The use of Pacritinib should focus on three major types of adverse reactions: bleeding risk, cardiac toxicity, and gastrointestinal reactions, ...
Common side effects of Lifnua tablets, such as nausea, rash, and fatigue, can be effectively managed through targeted measures. The following a...
The use of Lifnua tablets requires special attention to liver function monitoring, photosensitive reaction prevention, and drug interaction man...
